Sljedeći

Auto Play

Dr. Andrew Brohl at ASCO 2023: Abstract No. 9534

2 Pogledi • 07/17/23
Udio
Ugraditi
administrator
administrator
Pretplatnici
0

At ASCO 2023, Moffitt's Dr. Andrew Brohl discusses a phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Prikaži više
0 Komentari sort Poredaj po
Komentari na Facebooku

Sljedeći

Auto Play